Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEO accession GSE227717 is currently private and is scheduled to be released on Apr 09, 2028.

ABSTRACT: GEO accession GSE227717 is currently private and is scheduled to be released on Apr 09, 2028.

PROVIDER: PRJNA946710 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Effect of Kdm4a knockdown (KD) on gene expression in mosue PTR NEPC cells derived from Pb-Cre+,Pten f/f, Trp53 f/f, Rb1 f/f NEPC mouse model

Project description:To investigate the role of KDM4A in the regulation of gene expression in NEPC cells, we established Kdm4a KD cell lines in which Kdm4a gene has been knocked down by shRNA. We then performed gene expression profiling analysis using data obtained from RNA-seq of 4 different cells at two time points.

2026-01-21 | GSE227717 | GEO

KDM4A promotes NEPC progression through regulation of MYC expression [ChIP-seq]

Project description:Neuroendocrine prostate cancer (NEPC) represents one of the most lethal forms of prostate cancer (PCa) and lacks life-prolonging treatment. Incidence NEPC is increased due to the widespread use of AR pathway inhibitors (ARPIs) in the treatment of non-metastatic CRPC and hormone-sensitive metastatic tumors. Here we identified histone lysine demethylase KDM4A as a key player in NEPC progression and an effective therapeutic target. We performed ChIP-seq to identify KDM4A target genes in human NEPC cell line 144-13.

2026-01-28 | GSE227688 | GEO

Identify FOXA2-interacting proteins in NEPC cells

Project description:Following extensive treatment with androgen receptor (AR) pathway inhibitors, a significant number of metastatic prostate cancer develop treatment resistance, and approximately 20% of these castration-resistant prostate cancers (CRPC) transdifferentiate, at least partially, into neuroendocrine (NE) prostate cancer (NEPC).In human cancer, FOXA2 is highly expressed in most of NEPC and a small portion of CRPC patients, has been suggested as a marker of NEPC and elevated in other NE lineage cancers including SCLC. In addition, preclinical studies demonstrated that Foxa2 is required for NEPC tumor growth and metastasis in TRAMP mouse model and associated with NEPC transformation in Pten, Trp53, and Rb1 triple knockout mouse model. However, whether FOXA2 is an essential driver of NEPC, and the underlying mechanism in shaping epigenetic landscape of NEPC is largely unknown.

2025-06-12 | PXD061127 | Pride

Identify FOXA2-interacting proteins in NEPC cells

2025-06-12 | PXD061080 | Pride

Whole exome sequencing of Rb1 and Trp53 deficient (RP) SCLC mouse model

Project description:Whole exome sequencing of a cell line derived from an Rb1 and Trp53 genetically engineered mouse model (GEMM) to assess the baseline copy number landscape of the cells prior to experimental modification.

2019-07-09 | E-MTAB-7412 | biostudies-arrayexpress

KDM4A promotes NEPC progression through regulation of MYC expression [ChIP-seq]

Project description:KDM4A promotes NEPC progression through regulation of MYC expression [ChIP-seq]

| PRJNA946650 | ENA

Comparison of gene expression patterns of two SCLC genetically-engineered mouse models; Rb1 floxed, Trp53 floxed, LSL-Myc T58A-IRES-Luc vs. Rb1 floxed, Trp53 floxed, Rbl2 (p130) floxed

Project description:Myc expression cooperates with Rb1 and Trp53 loss in mouse lungs to generate rapid, aggressive, highly metastatic and neuroendocrine-low tumors that are similar to human variant subset of SCLC with high NEUROD1 expression. Targeted drug screening reveals that mouse and human MYC-driven SCLC are vulnerable to Aurora kinase inhibition in combination with chemotherapy in vivo.

2017-01-12 | GSE89660 | GEO

Whole exome sequencing of Rb1 and Trp53 deficient (RP) SCLC mouse model

Project description:Whole exome sequencing of Rb1 and Trp53 deficient (RP) SCLC mouse model

| PRJEB29872 | ENA

DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [RRBS]

Project description:Aberrant DNA methylation has been implicated as a key driver of prostate cancer lineage plasticity and histologic transformation to neuroendocrine prostate cancer (NEPC). DNA methyltransferases (DNMT) are highly expressed, and global DNA methylation levels are elevated in NEPC. We identified that deletion of DNMT genes decreases expression of neuroendocrine lineage markers and markedly reduced NEPC tumor development and metastasis in vivo. Decitabine, a global DNMT inhibitor, significantly attenuated tumor growth in NEPC patient-derived xenograft (PDX) models, as well as RB1-deficient castration-resistant prostate adenocarcinoma (CRPC) models compared with RB1-proficient CRPC. We further discovered that DNMT inhibition increased expression of B7-H3, an emerging druggable target, via demethylation of B7-H3 CpG islands. We tested DS-7300a, a novel antibody-drug conjugate (ADC) targeting B7-H3, alone and in combination with decitabine. There was potent single agent antitumor activity of DS-7300a in both CRPC and NEPC models bearing high expression of B7-H3. In B7-H3 low models, combination therapy of decitabine plus DS-7300a resulted in a synergistic response. Overall, we report that DNMT inhibition is a novel therapeutic target for NEPC and RB1-deficient CRPC and may sensitize B7-H3-low prostate cancer to the ADC DS-7300a through increasing target expression. NEPC and RB1-deficient CRPC represent prostate cancer subgroups with poor prognosis. The development of novel biomarker-driven therapeutic strategies for this population may ultimately help improve patient outcomes.

2024-03-27 | GSE216050 | GEO

DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 [22Rv1sgRB1]

2024-03-27 | GSE216713 | GEO